Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Orlistat has been used as an inhibitor:of fatty acid synthase in long-term estrogen-deprived (LTED) variant cell linesof lipase in screening lipase inhibition by raspberry extractin in vitro pancreatic lipase activity assay

Biochem/physiol Actions

Orlistat, used in obesity research, is a pancreatic lipase inhibitor that acts locally in the gastrointestinal tract to inhibit lipase.

Orlistat impairs intestinal fat absorption and is effective in weight management. It is regarded as a safe drug for treating obesity. It delays the progression of type 2 diabetes mellitus especially in obese and improves glycemic parameters. Long term usage of orlistat results in improved weight reduction and it may not contribute in colorectal carcinogenesis.

Features and Benefits

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Other Notes

Solution is not completely clear, small particles may remain floating.

Packaging

25, 100 mg in glass bottle